Blood Cancers

After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Researchers have found an increased frequency of severe maternal morbidity and obstetric complications among women who received a diagnosis of a hematological malignancy during pregnancy.

The risk of cardiovascular disease is elevated in cancer survivors, regardless of treatment, and is influenced by cancer type and treatment-related factors.

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.

With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my own pace.

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.

An expert explained the burden that red blood cell transfusions can place on patients with MDS.

Having myelodysplastic syndromes has taught me to cherish every day and to pursue the things that matter to me, like publishing a book I’ve been writing.

The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy.

Bispecific antibodies connect the immune system with cancer cells. They offer an efficacious treatment option, but there are side effects.

In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.

Just like athletes in the Olympics, it's important for cancer survivors to keep track of everything they feel and to know their bodies well.

The National Comprehensive Cancer Network now recommends Rytelo for patients with myelodysplastic syndrome who require blood transfusions.

Eighty percent of patients with relapsed or refractory Waldenstrom’s macroglobulinemia responded to treatment with iopofosine I 131, researchers found.

Researchers identified five traits that may increase a person’s chance of experiencing polycythemia vera progression.

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia had better MRD statuses after receiving Iclusig, compared with Gleevec.

Contrary to past research, blood cancer survivors may have safe and successful pregnancies up to 10 years after an allogeneic stem cell transplant.

Although MDS didn’t leave physical scars, the invisible ones, like side effects from treatment, are ones that linger.

More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.

For patients with MDS who benefit from delaying transplants, it’s important to take care of their health while savoring their time before transplant.

From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.

As a cancer survivor, I realize that life doesn’t always go the way we think it will, but it doesn’t erase the guilt.

Approximately half of the patients with MDS who responded to treatment with Rytelo went a year without needing a blood transfusion, one expert explained.

The Food and Drug Administration has approved Rytelo to treat certain patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.

Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl.

The safety profile of 200 milligrams and 300 milligrams of oral Ongureg were similar in patients with lower- to intermediate-risk MDS.